Wire Stories
-
437Nissan Demonstrates Autonomous-Drive Mobility Services Progress on Public Roads
YOKOHAMA, Japan–(BUSINESS WIRE)–Nissan has commenced demonstrations of a prototype vehicle equipped with its in-house-developed, autonomous drive technologies – showcasing progress in its...
-
450Other World Computing Introduces Intel Thunderbolt Share for the Thunderbolt Go Dock
Exciting New Application from Intel Enables Fast PC-to-PC Connectivity TAIPEI, Taiwan–(BUSINESS WIRE)–#Intel—Other World Computing – the leading solution provider of computer hardware,...
-
424Stronger Than Ever: Adani Portfolio Delivers Record Performance
45% EBITDA growth in FY24, EBITDA reaches USD 10 Bn Adani Portfolio EBITDA increased to USD 10 Bn, up by record 45%...
-
458Denodo Integrates NVIDIA NIM Inference Microservices to Accelerate and Optimize AI Capabilities for Enterprises
Integration enhances the Denodo Platform, providing enterprise customers with faster, more secure, and fully scalable AI capabilities PALO ALTO, Calif.–(BUSINESS WIRE)–Denodo, a...
-
495Denodo Opens ME Regional Head Office in Kingdom of Saudi Arabia to Meet Growing Demand for Data Management and AI
At the office opening today, Ángel Viña, CEO of Denodo will be joined by Dr. Shaikha Dheya Bint Ebrahim Al Khalifa and...
-
644ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
DESTINY-Breast06 results show Daiichi Sankyo and AstraZeneca’s ENHERTU is the first HER2 directed medicine and antibody drug conjugate to demonstrate clinically meaningful...
-
441“Experience the Luxury of Japanese Tradition and Cuisine” Reservations for the New Inbound Experience Tour in Osaka’s Tondabayashi Begin on June 1, 2024!
OSAKA, Japan–(BUSINESS WIRE)–The city of Tondabayashi in Osaka is excited to announce a new inbound tour by “SABIWabisabi,” aimed at revitalizing the...
-
464Takeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin Lymphoma
− Four-year Analysis Conducted by GHSG Reported ADCETRIS + ECADD Combination Improved Progression-Free Survival, Showing Superior Efficacy and Tolerable Safety Profile in...
-
463Accutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
– Differentiated Mechanism of Action of a Chimeric Degrader as Compared to Fulvestrant and Novel SERDs – – Treatment with AC699 Monotherapy...
-
577The World’s Light Painting Masters and GAC Work Together to Create a Chinese Giant Light-Painted Dragon That Shines in Dubai for the First Time
GUANGZHOU, China–(BUSINESS WIRE)–Coinciding with the Chinese Year of the Dragon in 2024, in order to celebrate the 40th anniversary of the establish...
